Prospective Grant of an Exclusive Patent License: Anti-CD56 as an Antibody-Drug Conjugate (“ADC”) or Non-ADC To Target Glioblastoma Either Alone or in Combination With Other Potential Immuno-Oncology Drugs.

Resumo

The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this notice to Connectyx Technologies Holdings Group ("Connectyx") located in Boca Raton, FL.